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A B S T R A C T
This naturalistic study analysed the association between cumulative lifetime antipsychotic dose and cognition in
schizophrenia after an average of 16.5 years of illness. Sixty participants with schizophrenia and 191 controls
from the Northern Finland Birth Cohort 1966 were assessed at age 43 years with a neurocognitive test battery.
Cumulative lifetime antipsychotic dose-years were collected from medical records and interviews. The
association between antipsychotic dose-years and a cognitive composite score based on principal component
analysis was analysed using linear regression. Higher lifetime antipsychotic dose-years were signiﬁcantly
associated with poorer cognitive composite score, when adjusted for gender, onset age and lifetime hospital
treatment days. The eﬀects of typical and atypical antipsychotics did not diﬀer. This is the ﬁrst report of an
association between cumulative lifetime antipsychotic dose and global cognition in midlife schizophrenia. Based
on these data, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance at
age 43 years. Potential biases related to the naturalistic design may partly explain the results; nonetheless, it is
possible that large antipsychotic doses harm cognition in schizophrenia in the long-term.
1. Introduction
Neurocognitive deﬁcits occur in the majority of persons with
schizophrenia (Heinrichs and Zakzanis, 1998; Keefe et al., 2005).
They are present before the ﬁrst psychotic episode, remain relatively
stable over the illness course (Bora and Murray, 2014; Zipursky et al.,
2013) and are strongly associated with functional outcome (Rajji et al.,
2014).
Antipsychotic medication is the foundation of treatment recom-
mendations in schizophrenia, yet the associations of antipsychotic
medication with cognition, especially in the long-term, after 5 or more
years of illness, remain largely unclear (Husa et al., 2014). The
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cognitive eﬀects of antipsychotic medication have mostly been studied
early in the course of illness in relatively short follow-ups ranging from
1 to 3 weeks to 2–3 years. Meta-analyses of these studies have found
mild to moderate cognitive improvements associated with the use of
both atypical (Désaméricq et al., 2014; Woodward et al., 2005) and
typical (Mishara and Goldberg, 2004) antipsychotic medication in
schizophrenia.
However, naturalistic, cross-sectional studies have suggested that
higher doses of antipsychotics (Élie et al., 2010; Hori et al., 2006;
Torniainen et al., 2012) or antipsychotic polypharmacy (Hori et al.,
2006) may be associated with poorer cognitive functioning in schizo-
phrenia, supported also by the ﬁnding of a positive eﬀect of dose-
reduction on cognition (Kawai et al., 2006; Takeuchi et al., 2013).
Very little is known about the eﬀects of antipsychotic medication in
the long-term (Leucht et al., 2012). In particular, the eﬀects of several
years or lifetime treatment with antipsychotics on global cognition in
schizophrenia have not yet been studied. Because many schizophrenia
patients receive antipsychotic treatment for several years or perma-
nently, it is imperative to study the eﬀects of not only short-term but
also lifelong antipsychotic treatment. Randomised controlled trials
(RCTs) are able to primarily determine the eﬃcacy and adverse eﬀects
of a treatment, but they do not allow a more detailed and long-term
assessment of adverse eﬀects (Young et al., 2015). Naturalistic
samples, however, oﬀer an optimal setting for investigating the long-
term eﬀects of medication (Wang et al., 2011), that often are
impossible to study in RCTs. In the Northern Finland Birth Cohort
1966 (NFBC 1966), higher lifetime cumulative doses of antipsychotic
medication were associated with poorer performance at age 34 and a
decline in verbal learning and memory between ages 34 and 43 years in
schizophrenia (Husa et al., 2014). We wanted to continue this research
line to investigate the eﬀects of lifetime cumulative dose of antipsy-
chotic medication on a more comprehensive measure of cognition in
midlife in a larger, partly overlapping sample.
This study aimed to analyse the association between cumulative
lifetime antipsychotic dose and cross-sectional global cognition in
schizophrenia at the age of 43 years. Our hypothesis was that higher
lifetime antipsychotic dose would be associated with poorer cognition,
even when potential confounders, such as severity and duration of
illness, are taken into account.
2. Methods
2.1. Sample
2.1.1. Participants
The participants of this study were members of the Northern
Finland Birth Cohort 1966. The NFBC 1966 is an unselected, general
population birth cohort identiﬁed during mid-pregnancy based on an
expected delivery date during 1966 in the provinces of Lapland and
Oulu. It comprises 12 058 live-born children, representing 96% of all
births in the region (Rantakallio, 1969). Permission to gather data was
obtained from the Ministry of Social and Health Aﬀairs. The study
design was approved by the Ethical Committee of the Northern
Ostrobothnia Hospital District. The study was carried out in accor-
dance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.
2.1.2. Case identiﬁcation
The NFBC 1966 members with a lifetime psychosis diagnosis were
identiﬁed using data from national registers. Psychosis diagnoses by
the end of 1997 were detected from the Care Register for Health Care
(formerly Finnish Hospital Discharge Register) and these diagnoses
were validated using hospital notes (Isohanni et al., 1997; Moilanen
et al., 2003). In addition, newer psychosis cases were detected based on
Care Register for Health Care on those registered ﬁrst time for a
psychosis between 1998 and 2008; Social Insurance Institution of
Finland register data on sick leaves or disability pensions due to
psychosis, or the right to reimbursement for psychoactive medication
due to psychosis by the end of 2008; or having reported a psychosis or
current antipsychotic use (at least 300 mg chlorpromazine equivalent)
in 1997 in a questionnaire data collection (Haapea et al., 2010).
Based on this procedure, 257 NFBC 1966 members with a
psychosis diagnosis and known address were invited and 99 (38.5%)
individuals participated in a psychiatric interview and examination in
2008–2011 at an average age of 43 years. The examination included
the SCID I interview (First et al., 2002) leading to DSM-IV lifetime
diagnosis. Based on diagnostic interview and information from na-
tional registers, 69 individuals had a diagnosis of schizophrenia
spectrum disorder. In the end, 60 (87.0%) were able to complete the
cognitive test battery and had adequate information on antipsychotic
medication. Of these 50 (83%) had a DSM-IV lifetime diagnosis of
schizophrenia, 6 (10%) schizoaﬀective, 2 (3%) schizophreniform and 2
(3%) delusional disorder. Hereafter, the term schizophrenia is used for
schizophrenia and other schizophrenia spectrum disorders. Part of this
sample (40 cases, 67%) went through the same diagnostic interviews as
well at 34 years of age when participating in another psychiatric
examination where we analysed associations between lifetime anti-
psychotic medication and change of verbal learning and memory in
schizophrenia between ages 34 and 43 years (Husa et al., 2014). The
mean duration of illness of the sample was 16.5 years (SD 6.0) and
average age was 43.1 years (SD 0.8).
In addition, 450 non-psychotic NFBC 1966 members from all
around Finland were invited to participate in the same psychiatric
interviews and cognitive assessment in 2008–2011. 191 (42.4%)
control subjects with an average age of 43.8 years (SD 0.8) and
available cognitive test results were included in the ﬁnal analyses.
Written informed consent was obtained from all cases and controls.
Participating cases did not diﬀer from non-participating cases in
gender, number of cumulative lifetime hospital treatment days or
occupational status. Compared to non-participants, participating cases
had signiﬁcantly lower education (basic education 28% vs. 15%,
secondary education 62% vs. 85%, tertiary education 10% vs. 0%)
(p=0.001), lower age of illness onset (mean 30.1 years vs. 26.6 years)
(p=0.002), they were more often on a disability pension (26% vs. 50%)
(p=0.001), and had more often diagnosis of narrow schizophrenia (68%
vs. 84%) (p=0.024). Participating controls did not diﬀer from all non-
psychotic members of the NFBC 1966 in gender, education or disability
pension status. Compared to non-participants, participating controls
were more often working (71% vs. 95%) (p < 0.001).
2.2. Data on antipsychotic medication
Information on the lifetime use of antipsychotic medication, until
the day the person was examined in the 43-year study, was gathered in
2007–2014 by a careful review of hospital, outpatient and health centre
medical records of all cases from everywhere in Finland. This informa-
tion was used to calculate the cumulative lifetime antipsychotic dose,
expressed as dose-years of a daily dose of 100 mg chlorpromazine
equivalent. Medication data was not only based on prescribed medica-
tion but if there was indication that a patient had not taken medication
it was taken into account in the estimation of lifetime doses. This
procedure is described in more detail in our previous work (Husa et al.,
2014). Additionally, current and earlier use of antipsychotic and other
psychiatric medication was ascertained in an interview in the 43-year
study.
2.3. Neuropsychological assessment and cognitive composite score
The neurocognitive performance of all cases and controls was
evaluated using a cognitive test battery comprising the Abstraction
Inhibition and Working Memory task (AIM; Glahn et al., 2000),
California Verbal Learning Test (CVLT; Delis et al., 1987), Visual
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Object Learning Test (VOLT; Glahn et al., 1997), Verbal ﬂuency (Lezak
et al., 2004), Visual series (WMS-III; Wechsler, 2008), Vocabulary
(WAIS-III; Wechsler, 2005), Digit Span (WAIS-III) and Matrix reason-
ing (WAIS-III). The cognitive tests were chosen for the versatile
assessment of diﬀerent aspects of cognitive functioning, including
executive function, working memory, verbal and visual learning,
vocabulary and visual reasoning. From these tests, the following
variables were obtained and used in analyses: total score of the ﬁrst
ﬁve learning trials of CVLT and total scores of all other cognitive tests.
Global cognitive performance (cognitive composite score) was based on
a principal component analysis (PCA) of these eight cognitive test
variables (see Section 2.5).
2.4. Background variables and covariates
The analyses were adjusted for gender, age of illness onset, markers
of severity of illness (logarithmic transformation of cumulative lifetime
number of psychiatric hospital treatment days until the study, remis-
sion, PANSS positive, negative and disorganisation symptoms), educa-
tional level and benzodiazepine use at the time of the study.
Age of illness onset was veriﬁed from medical records and deﬁned
as the age when the subject had ﬁrst evident psychotic symptoms.
Level of basic education (O level, 9 years or A level, 12 years) and
vocational education (none, course or school, currently studying,
college, polytechnic, or university) was obtained in a questionnaire in
the 43-year study. These were combined as the level of education:
Basic=O level with low vocational education (none, course or school, or
currently studying), secondary=O level with high vocational education
(college, polytechnic, or university), or A level with low vocational
education, and tertiary=A level with high vocational education.
The occupational status of the subjects at the time of the 43-year
study was classiﬁed into two categories: all subjects were classiﬁed as
(1) working if they were studying, on maternity leave or in full-time or
part-time work and (2) not working if they were unemployed, retired or
outside of working life for other reasons. Information was gained in the
interview at the 43-year study and for those with missing information it
was ascertained from Finnish Centre for Pensions registers.
School marks at 16 years of age were based on information acquired
from registers of the national application system for secondary educa-
tion after compulsory schooling (Isohanni et al., 1998). The Finnish
school marks range from 4 to 10, where 4 is deﬁned rejected, 5–6 poor,
7–8 satisfactory and 9–10 excellent. The mean scores of all subjects
were calculated from school reports. The school subjects included the
following theoretical subjects: native language, reading; native lan-
guage, literal; second, third, fourth and ﬁfth language; mathematics;
chemistry; physics; history; biology; geography; religion and civics.
Also the following practical subjects were included: physical education,
music, drawing, craft, domestic science, commercial subjects, type-
writing and agriculture.
Alcohol abuse diagnosis includes subjects with an earlier or current
diagnosis of both alcohol abuse and dependency. The information was
ascertained in the SCID I interview at the 43-year study.
PANSS (Positive and Negative Syndrome Scale; Kay et al. (2000))
scores were obtained in a PANSS speciﬁc interview at the 43-year
study. PANSS total symptoms were used to measure psychopathologi-
cal symptoms from the period of 1 week before the interview and they
were divided into symptomatic categories of positive, negative and
disorganisation symptoms based on the model described by van der
Gaag et al. (2006). Additionally, PANSS was used to determine
remission status (described below).
The Severity of Illness subscale of the CGI (Clinical Global
Impression; Guy, 2000) ranges from 1 (not ill at all) to 7 (among the
most extremely ill), and was included in the interview at the 43-year
study.
Information on the cumulative number of hospital treatment days
of the cases was derived from the Care Register for Health Care
(formerly Finnish Hospital Discharge Register).
Drug Attitude Inventory (DAI-10; Awad, 1993) is a questionnaire
which assesses attitude towards antipsychotic medication that was a
part of the 43-year study. DAI-10 includes 10 dichotomic (yes/no)
statements that were the most sensitive in separating between good
and poor adherence in a longer 30-question version (DAI-30; Hogan
et al., 1983) that was designed to predict adherence to antipsychotic
treatment. In DAI-10 the total score ranges between −10 and +10 with
a higher value reﬂecting better adherence.
Psychiatric treatment status was based on information from inter-
view at the 43-year study, where the participants were asked about
previous and current psychiatric treatment contacts (place and time of
starting the contact, frequency of visits). This information was classi-
ﬁed into four categories: no treatment contact, non-regular outpatient
treatment (less frequent than once per month or of unknown
frequency), regular outpatient treatment (visits in the mental health
oﬃce or in a few cases outpatient rehabilitation group at least once and
mostly 1–4 times per month), and inpatient/institution (if the case was
in psychiatric hospital treatment or lived in a sheltered home).
Remission was determined by the Andreasen symptomatic criteria
(Andreasen et al., 2005), the symptoms were required not to be present
at the time of the assessment and additionally the subject had to not
have been in psychiatric hospital treatment for 6 months prior to the
study in order to be classiﬁed as being in remission.
2.5. Statistical analyses
Mean cognitive test scores and cognitive composite scores of cases
and controls were compared using independent samples t-tests.
The measure of global cognitive performance was based on a
principal component analysis (PCA) of cognitive test variables
(Immediate free recall of trials 1–5 of CVLT, total scores of VOLT,
AIM, Verbal ﬂuency, Visual series, Vocabulary, Digit Span and Matrix
reasoning) performed separately for cases and controls. Missing values
of cognitive tests were imputed by multiple imputing (20 diﬀerent
datasets) (Rubin, 1987) where missing values were predicted based on
non-missing cognitive test values. The method of imputation was
MCMC and model type for scale cognition scores was linear regression.
Two cases and 3 controls did not have VOLT score, 1 case did not have
AIM score, 1 control did not have CVLT or VOLT scores, 3 cases and 2
controls did not have VOLT or AIM scores, 1 control was missing all
other but CVLT, VOLT and AIM scores. The PCA resulted in one
cognitive factor (cognitive composite score) for cases and two factors
for controls, which were forced into one factor to enable comparison
with cases. In the PCA eigenvalue was set as > 1. In cases, total
variance was explained 51.9% by one factor. Communalities of
cognitive tests ranged between 0.34 and 0.65 and factor loadings
between 0.51 and 0.78.
The association between the cognitive composite score and anti-
psychotic dose-years was analysed using linear regression analysis only
in cases with schizophrenia. Dose-years of any antipsychotics were
used as a continuous variable in the primary analyses and dose-years of
typical and atypical antipsychotics separately in secondary analyses.
The natural logarithm of antipsychotic dose-years was used as the
predictor variable. The eﬀects of antipsychotic dose-years in the linear
regression models are presented with unstandardised regression
coeﬃcients (B) and their standard error (SE), standardised regression
coeﬃcients (Beta) and statistical signiﬁcance values. Furthermore,
using the model with only gender and age of illness onset as covariates,
we illustrate the eﬀect of antipsychotic dose with adjusted R2 statistics.
As sensitivity analyses, all regression analyses were performed with
inverse probability weighting for the variables in which the cases had
selective attrition (age of illness onset, educational level, occupational
status and diagnosis). Spearman's correlation was used to analyse the
association between the cognitive composite score, lifetime dose-years
of any antipsychotics and background variables. P-values < 0.05 were
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considered statistically signiﬁcant. The analyses were performed with
IBM SPSS Statistics 21 (IBM Corp., 2012).
3. Results
3.1. The characteristics of the sample
The characteristics of the sample are described in Table 1. The
sample consisted of 60 cases (33 males, 55%) with lifetime schizo-
phrenia and 191 non-psychotic controls (94 males, 49%).
3.2. The characteristics of medication use
At the time of the study antipsychotic medication was used by 51
(85%) cases and one (1%) control (Online supplement Table 1). Typical
antipsychotics were used by 19 (32%) and atypical antipsychotics by 43
(72%) cases. The distribution of individual antipsychotic agents during
lifetime use is described in more detail in Online supplement Table 2.
The cumulative lifetime antipsychotic doses and current antipsy-
chotic doses of cases are reported in Table 2. Median lifetime
antipsychotic dose-years as chlorpromazine equivalents were 29.2
dose-years for any antipsychotics, 9.6 for typical and 16.1 for atypical
antipsychotics.
3.3. Cognitive functioning of cases and controls
The original cognitive test scores of cases and controls and results
of the PCA are presented in Table 3. Cases performed signiﬁcantly
worse than controls on all cognitive tests and global cognition.
3.4. Correlations between antipsychotic dose-years, cognition and
covariates
Higher cognitive composite score was signiﬁcantly correlated with
lower lifetime dose-years of any antipsychotics (p=0.004), higher age of
illness onset (p=0.013), higher school marks at 16 years of age (p <
0.001) and lower disorganisation symptoms (p < 0.001) (Online sup-
plement Table 3). Higher lifetime dose-years of any antipsychotics were
signiﬁcantly correlated with lower age of illness onset (p < 0.001),
higher number of lifetime hospital treatment days (p < 0.001) and
higher positive (p=0.002), negative (p=0.009) and disorganisation
symptoms (p < 0.001) (Online supplement Table 3). DAI total score
did not correlate with cognition, lifetime antipsychotic dose-years of
any antipsychotics, age of illness onset, lifetime hospital treatment
Table 1
Characteristics of the sample.
Schizophrenia Controls
Sociodemographic factors
Sex, n (%)
Males 33 (55%) 94 (49%)
Education, n (%)a
Low 33 (56%) 71 (37%)
Middle 15 (25%) 46 (24%)
High 11 (19%) 73 (38%)
Occupational status, n (%)
Working 18 (30%) 182 (95%)
School marks at 16 years, mean (SD)a 7.5 (0.9) 7.7 (0.9)
Clinical factors
Alcohol abuse dg, n (%)a
Yes 6 (10%) 9 (5%)
Current use of alcohol (g/day), median
(IQR)a
1.2 (0–14.0) 5.7 (2.0–
14.4)
SOFAS, mean (SD)a 50.7 (16.8) 84.6 (10.0)
DAI, mean (SD)a 5.6 (4.1)
Onset age (years), mean (SD) 26.6 (6.3)
Number of hospital treatment days,
median (IQR)
210 (84–687)
Psychiatric treatment status, n (%)
No treatment contact 26 (43%)
Non-regular outpatient treatment 7 (12%)
Regular outpatient treatment 22 (37%)
Inpatient/institution 5 (8%)
Diagnosis, n (%)
Schizophrenia 50 (83%)
Schizophreniform disorder 2 (3%)
Schizoaﬀective disorder 6 (10%)
Delusional disorder 2 (3%)
Symptom severity
CGI, mean (SD) 4.5 (1.4)
PANSS, mean (SD)a 66.6 (23.5)
Remission, n (%)a
Yes 16 (28%)
SOFAS=Social and Occupational Functioning Assessment Scale, CGI=Clinical Global
Impression, DAI=Drug Attitude Inventory, PANSS=Positive and Negative Syndrome
Scale, IQR=interquartile range. Psychiatric treatment status: non-regular outpatient
treatment=contact less than once per month or of unknown frequency, regular outpatient
treatment=1–4 times per month and inpatient/institution=being in psychiatric hospital
treatment or sheltered home.
a There were missing data for 1 case and 1 control in education, 1 control and 2 cases
in school marks at 16 years, 1 control in alcohol abuse dg, 1 case and 1 control in current
use of alcohol, 2 controls in SOFAS, 7 cases in DAI, 2 cases in PANSS, 2 cases in
remission.
Table 2
Lifetime antipsychotic dose-yearsa and current antipsychotic doseb in schizophrenia
(n=60).
Lifetime antipsychotic
dose-years Md (IQR)
Current antipsychotic
dose Md (IQR)
Any antipsychotics 29.2 (12.7–69.6) 225 (106.3–500.0)
Typical
antipsychotics
9.6 (0.8–32.7) 0 (0–57.5)
Atypical
antipsychotics
16.1 (2.6–37.9) 200.0 (0–475.0)
Md=median, IQR=interquartile range.
a Kroken et al. (2009).
b Chlorpromazine equivalents.
Table 3
Original values of the cognitive tests and the cognitive composite score based on principal
component analysis in schizophrenia (n=60) and controls (n=191).
Schizophrenia mean
(SD)
Controls mean
(SD)
Siga
AIM, Total score 41.5 (8.0) 48.3 (5.0) < 0.001
CVLT, Immediate free
recall of trials 1–5
43.7 (15.4) 55.2 (9.0) < 0.001
VOLT, Total score 60.1 (9.8) 67.7 (5.4) < 0.001
Verbal ﬂuency, Total score 47.5 (12.9) 58.4 (12.3) < 0.001
Visual series (WMS-III),
Total score
15.0 (4.1) 17.8 (2.8) < 0.001
Vocabulary (WAIS-III),
Total score
34.1 (14.7) 45.3 (11.4) < 0.001
Digit span (WAIS-III),
Total score
14.1 (3.9) 16.4 (3.9) < 0.001
Matrix reasoning (WAIS-
III), Total score
14.4 (5.8) 19.5 (3.6) < 0.001
Cognitive composite scoreb −0.98 (1.2) 0.29 (0.7) < 0.001
AIM=Abstraction Inhibition and Working Memory task, CVLT=California Verbal
Learning Test, VOLT=Visual Object Learning Test, WAIS-III=Wechsler Adult Intelli-
gence Scale – Third Edition, WMS-III - Wechsler Memory Scale – Third Edition.
a Diﬀerence between cases and controls.
b Principal Component Analysis. Rotation method: Promax with Kaiser
Normalisation.
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days, PANSS symptoms or school marks at 16 years of age (Online
supplement Table 3).
3.5. The association between lifetime cumulative antipsychotic dose-
years and global cognitive functioning
Higher lifetime cumulative dose-years of any antipsychotics were
signiﬁcantly associated with poorer cognitive composite score (p <
0.001), when adjusted for gender and age of illness onset (p=0.005)
(Table 4). This association remained signiﬁcant, when adjusted (in
addition to gender and age of illness onset) for remission (p=0.026),
lifetime cumulative number of hospital treatment days (p=0.004),
educational level (p=0.004), and current use of benzodiazepines
(p=0.014) (Table 4). The association remained signiﬁcant also, when
gender, age of illness onset, remission, hospital treatment days and
educational level were all included in the same regression model
(p=0.016) (Table 4). However, the association between higher dose-
years of any antipsychotics and poorer cognition did not remain
signiﬁcant, when school marks at 16 years of age were taken into
account (Table 4). Fig. 1 demonstrates the unadjusted association
between cumulative lifetime dose-years of any antipsychotics and
cognitive composite score. Signiﬁcant associations between higher
antipsychotic dose-years and poorer cognition were found for both
typical and atypical antipsychotics, when adjusted for gender and age
of illness onset, educational level and for atypical antipsychotics also,
when adjusted for lifetime hospital treatment days, and for typical
antipsychotics, when adjusted for the current use of benzodiazepines
(Table 4). For the full results, please see Table 4.
Regarding adjustment for symptoms, the association between
higher dose-years of any antipsychotics and poorer cognition was
non-signiﬁcant, when adjusted for disorganisation symptoms
(p=0.437). When adjusted for positive symptoms (p=0.020), negative
symptoms (p=0.047) and gender, onset age, hospital treatment days,
educational level and positive and negative symptoms in the same
model (p=0.035) the association remained signiﬁcant (Table 5).
Signiﬁcant associations between antipsychotic dose-years and cog-
nition remained in sensitivity analyses completed in the original data
without imputation as well as in sensitivity analyses with inverse
probability weighting to rule out the possible bias caused by the
selective attrition of cases. In the original data without imputation
the only exception was that the association between atypical antipsy-
chotic dose-years and cognition did not remain signiﬁcant, when
adjusted for gender, age of illness onset and hospital treatment days.
With inverse probability weighting there were additional signiﬁcant
results for higher typical antipsychotic dose-years and poorer cognition
in models adjusted for gender, age of illness onset and remission
(p=0.046) or hospital treatment days (p=0.031) or negative symptoms
(p=0.034) and in the model adjusted for gender, age of illness onset,
hospital treatment days, educational level and positive and negative
symptoms (p=0.047). When cases with current benzodiazepine use
(n=11), an intellectual disability diagnosis (n=6) or alcohol abuse
diagnosis (n=6) were excluded from the analyses, the signiﬁcant
associations between any antipsychotics and cognition remained.
Data of the sensitivity analyses are not shown but are available on
request.
Table 4
The association between lifetime antipsychotic dose-years and cognitive composite score at 43 years of age in schizophrenia in linear regression analysis.
Covariates in the model Any antipsychotics Typical antipsychotics Atypical antipsychotics
B (SE) Beta Sig B (SE) Beta Sig B (SE) Beta Sig
Unadjusted −0.33
(0.09)
−0.44 < 0.001 −0.27
(0.08)
−0.43 < 0.001 −0.20
(0.08)
−0.31 0.015
Gender, onset agea −0.27
(0.10)
−0.36 0.005 −0.23
(0.11)
−0.37 0.036 −0.17
(0.08)
−0.26 0.028
Gender, onset age, remission −0.25
(0.11)
−0.33 0.026 −0.19 (0.12) −0.31 0.102 −0.15 (0.09) −0.23 0.085
Gender, onset age, hospital treatment daysb −0.33
(0.11)
−0.43 0.004 −0.23 (0.12) −0.36 0.050 −0.19
(0.09)
−0.29 0.036
Gender, onset age, educational level −0.28
(0.10)
−0.37 0.004 −0.24
(0.11)
−0.37 0.035 −0.18
(0.08)
−0.27 0.025
Gender, onset age, school marks at 16 yearsc −0.15 (0.09) −0.20 0.099 −0.09 (0.11) −0.14 0.407 −0.12 (0.07) −0.19 0.081
Gender, onset age, current use of benzodiazepines −0.24
(0.10)
−0.32 0.014 −0.22
(0.11)
−0.34 0.049 −0.14 (0.08) −0.22 0.086
Gender, onset age, remission, hospital treatment days, educational
level
−0.31
(0.13)
−0.41 0.016 −0.31 (0.19) −0.31 0.111 −0.27 (0.15) −0.27 0.072
Gender, onset age, remission, hospital treatment days, school marks
at 16 yearsb
−0.14 (0.12) −0.18 0.262 −0.08 (0.18) −0.08 0.660 −0.18 (0.13) −0.18 0.172
B=unstandardised regression coefficient, SE=standard Error, Beta=standardised regression coefficient, Sig=statistical significance. Statistically significant results in bold.
a The adjusted R2 of the model without antipsychotic dose-years was 0.135. When antipsychotic dose-years were included in the model, the corresponding R2s were 0.250 for any,
0.188 for typical and 0.203 for atypical antipsychotics.
b Lifetime cumulative number of hospital treatment days (logarithmic transformation).
c Mean of school marks at 16 years of age.
Fig. 1. The association between lifetime dose-years of any antipsychotics and cognitive
composite score at age 43 years in schizophrenia. Higher lifetime antipsychotic dose-
years associated with poorer cognitive composite score. (Beta coeﬃcient and statistical
signiﬁcance are from linear regression analysis with natural logarithm of dose-years of
any antipsychotics as the predictor variable).
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4. Discussion
In this study higher lifetime cumulative dose-years of any anti-
psychotics were signiﬁcantly associated with poorer global cognition at
the age of 43 years in schizophrenia, when the most important
confounding factors related to duration and severity of illness were
controlled for. However, the association did not remain when dis-
organisation symptoms and school marks at the age of 16 were taken
into account. The cognitive eﬀects of typical and atypical antipsychotics
were similar.
4.1. Comparison with previous studies
Nearly all evidence of the cognitive eﬀects of antipsychotics rests on
relatively short-term clinical trials which have found mild to moderate
cognitive improvements associated with both atypical (Désaméricq
et al., 2014; Woodward et al., 2005) and typical (Mishara and
Goldberg, 2004) antipsychotics in schizophrenia. However, a practice
eﬀect has been suggested to confound these ﬁndings of improvement
and antipsychotics may only have minimal eﬀects on cognition in the
short-term (Goldberg et al., 2010; Szöke et al., 2008).
The association between antipsychotic dose and cognition has not
been adequately analysed in the previous studies. Most studies
included in meta-analyses do not report antipsychotic doses (Irani
et al., 2011; Mesholam-Gately et al., 2009; Mishara and Goldberg,
2004). One meta-analysis of older people with schizophrenia (Irani
et al., 2011) and another meta-analysis of typical antipsychotics and
cognition (Mishara and Goldberg, 2004) did not ﬁnd a signiﬁcant
association between antipsychotic dose and cognition. However, one
meta-analysis found an association between higher antipsychotic dose
and poorer processing speed (Knowles et al., 2010).
Our group found an association between higher cumulative anti-
psychotic exposure and brain volume loss (Veijola et al., 2014) and
decline in verbal learning and memory (Husa et al., 2014) in the NFBC
1966 population (partially overlapping sample with the sample of this
article) between ages 34 and 43 years. Now we extend our earlier
ﬁndings by showing a signiﬁcant association between higher cumula-
tive antipsychotic dose and poorer global cognition at age 43 years in a
larger sample.
The discrepancy between some data from previous meta-analyses
and our present and earlier ﬁndings may be explained by diﬀerences in
the length of follow-up (up to 2–3 years vs. 16.5 years in our study),
setting (controlled vs. naturalistic), population (clinical vs. population-
based), antipsychotic dose variable (cross-sectional vs. longitudinal,
cumulative dose) as well as lack of reported medication dosage data
that limits the power to ﬁnd associations.
4.2. Interpretation of the results
Based on beta coeﬃcients (-0.26 to −0.44) the eﬀect sizes of the
signiﬁcant associations between higher lifetime antipsychotic dose and
poorer cognition in this study are moderate.
The association between antipsychotic dose-years and cognition
remained signiﬁcant when adjusting for positive and negative symp-
toms. However, it did not remain signiﬁcant when adjusting for
disorganisation symptoms or school marks at 16 years of age.
Disorganisation symptoms, such as stereotyped thinking, poor atten-
tion, disorientation, conceptual disorganisation and diﬃculty in ab-
straction (van der Gaag et al., 2006), in fact are clinical manifestations
of cognitive deﬁcits and inversely correlate with cognition (Minor and
Lysaker, 2014). Premorbid school performance is associated with
cognitive functioning at ﬁrst-episode (Fuller et al., 2002) and poorer
premorbid school performance predicts cognitive decline in midlife
schizophrenia (Rannikko et al., 2015). In our data both disorganisation
symptoms and school marks had signiﬁcant and strong correlations
with cognition. Thus, it may that the reduction of signiﬁcant associa-
tion in this case therefore reﬂects more overadjustment (Schisterman
et al., 2009) rather than a genuine lack of association between higher
lifetime antipsychotic dose and poorer cognition. Disorganisation
symptoms had signiﬁcant correlation with higher lifetime antipsycho-
tics dose, whereas school marks at the age of 16 years did not. It is also
possible that a part of the variance in the association between
antipsychotic dose-years and cognition is explained by disorganisation
symptoms and to some extent by premorbid school performance.
This study did not ﬁnd diﬀerences in the cognitive eﬀects of typical
and atypical antipsychotics. The ﬁnding of similar eﬀect may reﬂect no
great diﬀerences between these groups or that due to small sample
sizes there is not enough statistical power to detect possible diﬀerences.
It is important to notice, that because most cases (85%) had used at
least 3 diﬀerent antipsychotic agents during their lives, it is impossible
to separate between the eﬀects of individual antipsychotic drugs on
cognition in this sample.
4.3. Theoretical discussion
Evidence of the beneﬁts of antipsychotic treatment is persuasive
only during the ﬁrst years of illness (Leucht et al., 2012). There is
cumulating evidence that long-term and higher dose antipsychotic
treatment may have potentially harmful eﬀects on brain structure
(Andreasen et al., 2013; Fusar-Poli et al., 2013; Veijola et al., 2014)
and functioning (Abbott et al., 2013) as well as cognition (Husa et al.,
2014; Knowles et al., 2010). Cognitive deﬁcits in schizophrenia are
associated with hypoactive prefrontal cortex and D2 receptor antago-
nist antipsychotics may additionally decrease the hypodopaminergic
state of mesocortical pathways projecting to prefrontal cortex and
worsen negative symptoms and cognitive impairments (Liemburg
et al., 2012). Moreover, high-dose antipsychotic exposure resulting in
D2 occupancy above 80% has been associated with neurocognitive
impairment (Sakurai et al., 2013). In animal models, the adverse
eﬀects of antipsychotics on cognitive functioning have not occurred
Table 5
The association between lifetime antipsychotic dose-years and cognitive composite score at 43 years of age in schizophrenia in linear regression analysis, models adjusted with PANSS.a
Covariates in the model Any antipsychotics Typical antipsychotics Atypical antipsychotics
B (SE) Beta Sig B (SE) Beta Sig B (SE) Beta Sig
Gender, onset age, positive symptoms −0.25
(0.11)
−0.32 0.020 −0.20 (0.12) −0.31 0.098 −0.15 (0.09) −0.23 0.087
Gender, onset age, negative symptoms −0.20
(0.10)
−0.27 0.047 −0.19 (0.11) −0.30 0.084 −0.11 (0.09) −0.16 0.213
Gender, onset age, disorganisation symptoms −0.08 (0.10) −0.10 0.437 −0.08 (0.10) −0.13 0.445 −0.02 (0.08) −0.03 0.829
Gender, onset age, hospital treatment days, educational level, positive
symptoms, negative symptoms
−0.26
(0.12)
−0.34 0.035 −0.32 (0.19) −0.32 0.083 −0.19 (0.15) −0.19 0.227
B=unstandardised regression coefficient, SE=Standard Error, Beta=standardised regression coefficient, Sig=statistical significance. Statistically significant results in bold.
a The PANSS (Positive and Negative Syndrome Scale; Kay et al., 2000) was based on a PANSS speciﬁc interview and divided into positive, negative and disorganisation symptoms
based on the factor structure described by van der Gaag et al. (2006).
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immediately but only after three to six months and these eﬀects may be
mediated by alterations in cholinergic function in the brain (Terry and
Mahadik, 2007). In addition, sedative antipsychotic eﬀects conveyed by
histamine-1, muscarine and alfa-1-adrenergic receptors and 5-HT-2A
antagonistic eﬀects that inhibit glutaminergic function and may disturb
mesolimbic and mesocortical functions have been hypothesised to
explain negative cognitive eﬀects of antipsychotics (Stahl, 2008).
Dose reduction or discontinuation of antipsychotic treatment is
associated with better functional remission rates after 7 years
(Wunderink et al., 2013) and not using antipsychotics with fewer
psychotic symptoms and less hospital treatment in 20 years of
naturalistic follow-up in schizophrenia (Harrow et al., 2014). In the
NFBC 1966 sample, being antipsychotic-free was associated with better
outcome at age 34 years (Moilanen et al., 2013). Our results add to the
above mentioned studies, supporting the potentially harmful eﬀects of,
in particular, high doses of antipsychotics in the long-term.
4.4. Strengths and limitations
A fundamental strength is the naturalistic, population-based study
sample with extensive, prospectively collected information. Owing to
the observational setting it was possible to investigate long-term and
adverse eﬀects of medication which cannot be detected in short-term
clinical trials (Wang et al., 2011). The longitudinal data on lifetime
cumulative antipsychotic exposure is unique. Because we had access
also to medical records we were able to take into account known
periods when patients were not taking medications when estimating
lifetime antipsychotic doses, not only prescribed or purchased medica-
tion as most register or interview studies. Additionally, we measured
DAI-10 which has been shown to predict antipsychotic adherence in
some studies (Brain et al., 2013; Yang et al., 2012). Based on the DAI
total score (Table 1) the participants had good adherence to anti-
psychotic treatment. Also ﬁnding no correlation between the DAI score
at 43 years of age and lifetime antipsychotic dose or cognition (Online
supplement Table 3) may further support adherence not being a
signiﬁcant confounder of the association between higher antipsychotic
dose and poorer cognition. It should be noted, though, that we did not
have any measure of adherence during the whole illness course.
A limitation is the relatively small sample size which decreases
statistical power and likelihood to detect even moderate signals,
especially in smaller subsamples (for example analysing the eﬀects of
typical and atypical antipsychotics). A non-standard neuropsychologi-
cal test battery is also a potential limitation, though valid tests which
measure the most essential cognitive dimensions similarly to standar-
dised batteries (MATRICS, CANTAB, WAIS-III) were used. Because we
did not study cognitive change, we cannot ﬁnd out if the association
between higher antipsychotic dose and poorer cognition is temporal or
causal.
The selective attrition rising from the participating cases having
markers of more severe illness and poorer functioning (lower age of
illness onset and educational level, more often a narrow schizophrenia
diagnosis and disability pension) compared with non-participants may
introduce a bias in interpreting the results. However, in our population
based sample the participating cases also had characteristics related to
less severe illness and better functioning, e.g. 92% were outpatients,
43% even without psychiatric treatment contact and 28% were in
remission. This indicates that there were both poorly and well-
functioning cases in our sample. Moreover, based on the weighted
sensitivity analyses, the selective attrition did not signiﬁcantly aﬀect
the results of this study.
Even though the naturalistic design has its limitations e.g. in
ﬁnding causal associations, RCTs are not possible or realistic in long
follow-ups and naturalistic studies are the only option to get new
information. Additionally, our epidemiologically sound, population
based sample of mostly outpatients and some people without psychia-
tric treatment contact may reﬂect less severe illness than in many
clinical settings and make the results less generalisable to some severe
clinical populations but more generalisable to all individuals with
schizophrenia.
To decrease the risk of residual confounding in our naturalistic
setting with a long follow-up, the most important confounders related
to duration and severity of illness were taken into account. However,
individuals with more severe illness and poorer course of cognition
may receive higher doses of antipsychotic medication, making higher
doses a marker of a more serious illness course rather than cause of
cognitive decline. Nonetheless it cannot be ruled out, especially with
the cumulating evidence from other studies of potentially harmful
eﬀects of years of antipsychotic use on cognition, brain structures and
functioning, that the ﬁndings reﬂect a true causal association.
4.5. Conclusions
To our knowledge, this is the ﬁrst report of an association between
cumulative lifetime antipsychotic dose and global cognition in midlife
schizophrenia. Based on these data higher cumulative lifetime dose-
years of antipsychotics may be associated with poorer cognitive
performance at the age of 43 years. It is possible that large doses of
antipsychotics inﬂuence the natural course of schizophrenia in midlife,
for example by preventing or attenuating cognitive recovery.
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